Bococizumab PF-04950615; RN316|cas:1407495-02-6|西域试剂

Bococizumab PF-04950615; RN316,99.9%

产品编号：Bellancom-P99187| CAS NO：1407495-02-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99187		￥4200.00	杭州北京（现货）
Bellancom-P99187		￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Bococizumab PF-04950615; RN316

产品介绍

Bococizumab (PF-04950615) 是一种抗-人 PCSK9 的抗体抑制剂，可降低低密度脂蛋白胆固醇 (LDL-C) 水平。Bococizumab 可用于高胆固醇血症的研究。

生物活性

Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.

体外研究

体内研究

Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pregnant Sprague-Dawley (SD) rats
Dosage:	0, 10, 30, and 100 mg/kg
Administration:	Intravenous injection (i.v.)
Result:	Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.

体内研究

Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Pregnant Sprague-Dawley (SD) rats
Dosage:	0, 10, 30, and 100 mg/kg
Administration:	Intravenous injection (i.v.)
Result:	Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.